外科理论与实践

外科理论与实践 >

2023 , Vol. 28 >Issue 01: 53 - 57

DOI: https://doi.org/10.16139/j.1007-9610.2023.01.09

讲座

EB病毒阳性的胃癌与伴有淋巴样间质的胃癌——诊断及分子检测进展

展开
  • 上海交通大学医学院附属瑞金医院病理科，上海 200025

收稿日期: 2022-11-18

  网络出版日期: 2023-03-25

收起

Advances in diagnosis and molecular detection of EBV-positive gastric cancer and gastric cancer with lymphoid stroma

Expand
  • Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2022-11-18

  Online published: 2023-03-25

Fold

摘要

EB病毒阳性的胃癌与伴有淋巴样间质的胃癌均属于胃癌特殊病理亚型。其组织学形态、免疫学与遗传学特征存在部分重叠，却不完全相同。因此，这一组肿瘤不仅引起病理医师诊断上的困惑，同时也不利于临床治疗及后续研究。本文对这两种肿瘤以及与之相近诊断术语作详细介绍及对比，探讨其临床病理特征、遗传学改变、分子检测及治疗进展，并归纳总结现存争议及未来研究方向。

关键词： 胃癌; EB病毒; 淋巴样间质

本文引用格式

邓仕杰, 袁菲 . EB病毒阳性的胃癌与伴有淋巴样间质的胃癌——诊断及分子检测进展[J]. 外科理论与实践, 2023 , 28(01) : 53 -57 . DOI: 10.16139/j.1007-9610.2023.01.09

Abstract

Epstein-Barr virus-positive gastric cancer, as well as gastric cancer with lymphoid stroma, are the special pathological subtypes of gastric cancer. The histological morphology, immunological and genetic characteristics between two subtypes are overlapped to some extent, however, they are not identical. Therefore, there were not only the confusion in the diagnosis for pathologists but also perplexity in clinical treatment and following research caused by two subtypes of gastric cancer. In this article, the two cancers and other similar diagnostic terms were introduced and compared in detail. The clinicopathological features, genetic variation, molecular detection, and treatment progress were summarized combined with both current controversies and future directions of research.

Key words： Gastric cancer; Epstein-Barr virus; Lymphoid stroma

参考文献

[1] MURPHY G, PFEIFFER R, CAMARGO M C, et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location[J]. Gastroenterology, 2009, 137(3):824-833.
[2] LEE J H, KIM S H, HAN S H, et al. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis[J]. J Gastroenterol Hepatol, 2009, 24(3):354-365.
[3] LIM H, PARK Y S, LEE J H, et al. Features of gastric carcinoma with lymphoid stroma associated with Epstein-Barr virus[J]. Clin Gastroenterol Hepatol, 2015, 13(10):1738-1744.
[4] SETIA N, AHN S, HAN H S, et al. Predictive value of WHO classification for PD-L1 and Her2/Neu expression and distinct associations with protein expression based classification in gastric carcinoma[J]. Hum Pathol, 2019, 94:64-70.
[5] KIM S T, CRISTESCU R, BASS A J, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer[J]. Nat Med, 2018, 24(9):1449-1458.
[6] Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014, 513(7517):202-209.
[7] PULIGA E, CORSO S, PIETRANTONIO F, et al. Microsatellite instability in gastric cancer: between lights and shadows[J]. Cancer Treat Rev, 2021, 95:102175.
[8] AJANI J A, D'AMICO T A, BENTREM D J, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(2):167-192.
[9] LORDICK F, CARNEIRO F, CASCINU S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(10):1005-1020.
[10] FUKAYAMA M, USHIKU T. Epstein-Barr virus-associated gastric carcinoma[J]. Pathol Res Pract, 2011, 207(9):529-537.
[11] CHEN J N, HE D, TANG F, et al. Epstein-Barr virus-associated gastric carcinoma: a newly defined entity[J]. J Clin Gastroenterol, 2012, 46(4):262-271.
[12] SHINOZAKI-USHIKU A, KUNITA A, FUKAYAMA M. Update on Epstein-Barr virus and gastric cancer (review)[J]. Int J Oncol, 2015, 46(4):1421-1434.
[13] YAMADA L, SAITO M, THAR MIN A K, et al. Selective sensitivity of EZH2 inhibitors based on synthetic letha-lity in ARID1A-deficient gastric cancer[J]. Gastric Cancer, 2021, 24(1):60-71.
[14] MIMURA K, TEH J L, OKAYAMA H, et al. PD-L1 expression is mainly regulated by interferon gamma associa-ted with JAK-STAT pathway in gastric cancer[J]. Cancer Sci, 2018, 109(1):43-53.
[15] NAKANO H, SAITO M, NAKAJIMA S, et al. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms[J]. Sci Rep, 2021, 11(1):1982.
[16] HISSONG E, RAMRATTAN G, ZHANG P, et al. Gastric carcinomas with lymphoid stroma: an evaluation of the histopathologic and molecular features[J]. Am J Surg Pathol, 2018, 42(4):453-462.
[17] GONZALEZ R S, CATES J M M, REVETTA F, et al. Gastric carcinomas with lymphoid stroma: categorization and comparison with solid-type colonic carcinomas[J]. Am J Clin Pathol, 2017, 148(6):477-484.
[18] KANG W, TO K F. Are Epstein-Barr virus-positive and-negative gastric carcinomas, with lymphoid stroma, single entity or different entities?[J]. Clin Gastroenterol Hepatol, 2015, 13(10):1745-1747.
[19] KONO K, NAKAJIMA S, MIMURA K. Current status of immune checkpoint inhibitors for gastric cancer[J]. Gastric Cancer, 2020, 23(4):565-578.
[20] TORRE L A, SIEGEL R L, WARD E M, et al. Global cancer incidence and mortality rates and trends—an update[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(1):16-27.
[21] GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(1):42-54.
[22] SWEED D, SULTAN M M, MOSBEH A, et al. Lymphoe-pithelioma-like hepatocellular carcinoma: a case report and review of literature[J]. J Gastrointest Cancer, 2021.
[23] WANG J K, JIN Y W, HU H J, et al. Lymphoepithelioma-like hepatocellular carcinoma: a case report and brief review of literature[J]. Medicine (Baltimore), 2017, 96(51):e9416.
[24] SHINODA M, KADOTA Y, TSUJIKAWA H, et al. Lymphoe-pithelioma-like hepatocellular carcinoma: a case report and a review of the literature[J]. World J Surg Oncol, 2013, 11:97.
Options
文章导航

/

〈 〉